Sollievo Pharmaceuticals

When Minutes Matter

Claim My Business
Security Type
Common Stock
Healthcare & Medical
Min Investment
Offering Date
August 04, 2022
Expected Close Date
December 16, 2022
Target Raise
No. Investors
Security Price
Number of Employees
Short Term Debt
Cost of Goods
Long Term Debt
Net Income

Company Description

Sollievo Pharmaceuticals is seeking to improve safety for healthcare staff with our first product, Proviza. Proviza is a fast-acting sedative developed to address the rising incidence of injuries and abuse to healthcare staff when treating agitated and aggressive patients. Sollievo Pharmaceuticals is pre-revenue and in the development and scale-up stages.


StartEngine OWNERS Exclusive Click here to learn more

$200+ Investment
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.

Super Early Bird Bonus
Invest within the first four weeks and receive 20% bonus shares.





$500+ Investment
Company Bonus
Invest $500+ and receive 5% bonus shares.

$1,000+ Investment
Silver Bonus
Invest $1,000+ and receive 10% bonus shares.

$5,000+ Investment
Gold Bonus
Invest $5,000+ and receive 15% bonus shares.

$10,000+ Investment
Platinum Bonus
Invest $10,000+ and receive 20% bonus shares

Key Deal Facts

7 out of 10 emergency physicians say emergency department violence is increasing and half have been physically assaulted at work. Proviza was developed to address this public health crisis.*

We believe Sollievo has the potential of disrupting the estimated $1.2B global intramuscular agitation and aggression treatment market by introducing one of the fastest acting intramuscular solutions compared to competitors on the market today.**

Sollievo's leadership and consulting team represents more than 100 years of combined experience in the pharmaceutical and medical industries.

Management Team / Advisory Board Bios

Peter Schineller

Commercial Strategic Advisor

During his 35-year career, Mr. Schineller has held executive positions, CMO, SVP, and CCO at major pharmaceutical companies, including Novartis, Abbott, and Pfizer. He co-founded Veras Pharmaceuticals where he was the CCO. Novartis acquired the Veras product line. Mr. Schineller's success in commercializing drug products makes him an ideal advisor to guide the company's marketing and commercial launch strategies to ensure the successful uptake of its lead product Proviza. 
With Sollievo, Peter works on average 1 hour per week and on an as-needed basis. 

Anthony Coniglio, PharmD

Strategic Clinical/Commercial Advisor

Dr. Coniglio has focused his 30-year career in medical, commercial strategy, and business development at BMS, Pharmacia, and Medpointe. He founded his consulting practice to provide business development, medical, and marketing for major brands. At Sollievo, Dr. Coniglio will advise the company on the interface between clinical, marketing, and approval of Proviza. He will be instrumental in developing the strategy that ensures broad acceptance of Proviza, clearing the way for rapid hospital formulary approval. 
With Sollievo, Anthony works on average 1 hour per week and on an as-needed basis.
Amount Raised : $40,714
Reveal the Score by Voting
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
The value of the company compared to similar companies raising money from investors.

Security Description

Common stock is a security that represents ownership in a corporation.

Research Reports

No reports have been submitted

Become a Reporter